These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 16042689

  • 1. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [Abstract] [Full Text] [Related]

  • 2. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 3. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov 01; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

  • 4. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 01; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 5. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.
    Biol Blood Marrow Transplant; 2009 Dec 01; 15(12):1587-95. PubMed ID: 19896083
    [Abstract] [Full Text] [Related]

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 7. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Mohty M, Bagattini S, Chabannon C, Faucher C, Bardou VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, Ladaique P, Olive D, Viens P, Blaise D.
    Exp Hematol; 2004 Nov 01; 32(11):1097-102. PubMed ID: 15539088
    [Abstract] [Full Text] [Related]

  • 8. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov 01; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 9. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 10. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.
    Biol Blood Marrow Transplant; 2013 Jun 01; 19(6):981-7. PubMed ID: 23562738
    [Abstract] [Full Text] [Related]

  • 11. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI, Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT).
    Biol Blood Marrow Transplant; 2010 Oct 01; 16(10):1419-27. PubMed ID: 20399879
    [Abstract] [Full Text] [Related]

  • 12. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N.
    J Clin Oncol; 2008 Jan 20; 26(3):455-62. PubMed ID: 18086796
    [Abstract] [Full Text] [Related]

  • 13. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.
    Biol Blood Marrow Transplant; 2013 Jun 20; 19(6):934-9. PubMed ID: 23523970
    [Abstract] [Full Text] [Related]

  • 14. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS, Fenu S, Moleti ML, De Felice L, Girelli G, Arcese W.
    Haematologica; 2003 Mar 20; 88(3):315-23. PubMed ID: 12651271
    [Abstract] [Full Text] [Related]

  • 15. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
    Diaz MA, Vicent MG, Gonzalez ME, Verdeguer A, de la Rubia J, Bargay J, de Arriba F, Diez JL, Caballero D, Madero L, Brunet S, Spanish Group for Allogeneic Peripheral Blood Transplantation.
    Bone Marrow Transplant; 2004 Sep 20; 34(5):433-8. PubMed ID: 15273704
    [Abstract] [Full Text] [Related]

  • 16. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
    Martino R, Caballero MD, de la Serna J, Díez-Martín JL, Urbano-Ispízua A, Tomás JF, Odriozola J, León A, Canals C, San Miguel J, Sierra J.
    Bone Marrow Transplant; 2002 Jul 20; 30(2):63-8. PubMed ID: 12132043
    [Abstract] [Full Text] [Related]

  • 17. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D, Martino R, Sureda A, Canals C, Altés A, Briones J, Sanz MA, Parody R, Constans M, Villela SL, Brunet S, Sierra J.
    Eur J Haematol; 2005 Feb 20; 74(2):144-51. PubMed ID: 15654906
    [Abstract] [Full Text] [Related]

  • 18. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.
    Biol Blood Marrow Transplant; 2009 Jun 20; 15(6):704-17. PubMed ID: 19450755
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y, Suzuki R, Kuwatsuka Y, Yasuda T, Takahashi T, Tsujimura A, Sugimoto K, Oba T, Terakura S, Atsuta Y, Murata M, Ito M, Kodera Y, Miyamura K.
    Biol Blood Marrow Transplant; 2008 Jan 20; 14(1):43-9. PubMed ID: 18158960
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 20; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.